



**COMPUMED EXPANDS INTO OCCUPATIONAL HEALTHCARE: AGREEMENT WITH FORTUNE 50 CORPORATION WILL SUPPLY ECG OVER-READS IN WORKPLACE CLINIC NETWORK  
NEW COMPUMED CAPABILITY PROVIDES ECG OVER-READS WITH ANY THIRD PARTY MACHINES**

LOS ANGELES, May 19, 2009 -- CompuMed, Inc. (CMPD.OB) -- a medical informatics company serving the healthcare community with diagnostic software solutions -- today announced that it has expanded into the occupational telemedicine market by entering into an agreement to supply ECG over-reads through its CardioGram™ telecardiology service to a large unit of a Fortune 50 company with a network of company-owned workplace clinics servicing more than 40,000 employees.

Maurizio Vecchione, CompuMed's President and CEO, said, "Our move into occupational healthcare represents another possible expansion arena for the company's clinical care centralized ECG services. Increasingly employers, especially large ones, are in the front lines of having to provide specialized care. Our telecardiology service enables them to deliver specialist interpretation of ECGs at the point-of-care as they need it. Our solution is a cost-effective way to access cardiology expertise." He added that a confidentiality agreement precluded CompuMed from releasing the name of the company.

CompuMed's market expansion is the result of a new Electronic Medical Record (EMR) solution allowing CompuMed to receive ECGs and provide over-reads for any customer, anywhere, regardless of the type of ECG machine being used by that customer. Historically, the company was limited to clients with CompuMed ECG machines.

"We are excited about this important milestone for CompuMed," said Mr. Vecchione. "Now we can target customers with two new ways to send us ECGs to process. They can either transmit them electronically from their own communication enabled ECG machines or they can use a new broadband fax-to-e-mail system that we provide if their existing ECG machines do not have communication capabilities." This means that customers can access CompuMed's ECG over-reading services no matter what type or brand of ECG machine they are using in their facilities.

"This represents another example of how our commitment to electronic medical records impacts the safety, effectiveness and cost of healthcare by having the right information at the right place at the right time," Mr. Vecchione said. "CompuMed can help any healthcare provider that uses ECGs extensively into using integrated digital medical records, an important part of the Obama administration's challenge to computerize all medical records by 2014."

### **About CompuMed:**

CompuMed, Inc. (CMPD.OB) develops and markets products and services that combine telemedicine, medical informatics and advanced imaging. The CardioGram™ is one of the first telecommunication networks designed to remotely interpret electrocardiograms and is used by private practice, government and corporate healthcare providers nationwide. The OsteoGram® is a noninvasive diagnostic system that provides effective and accurate bone density measurement for screening for osteoporosis and assessing hip fracture risk. The OsteoGram has significant cost advantages over other technologies in the marketplace. The OsteoGram and CardioGram are cleared by the FDA and reimbursable by Medicare. CompuMed distributes its products worldwide both directly and through OEM partners. . Visit CompuMed on-line at [www.compumed.net](http://www.compumed.net).

*Statements contained in this press release that are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth, results of contracts and other financial results, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including statements concerning the Company's plans, objectives, expectations and intentions are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to uncertainties and risks including, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-KSB and Quarterly Reports on Form 10-QSB. All such forward-looking statements are expressly qualified by these cautionary statements. The Company expressly disclaims any obligation or undertaking to release*

*publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.*

**CONTACT:**

Susan Tellem - Tellem Worldwide, +1 (310) 479-6111 x.1.  
stelllem@tellem.com